The clinical syndrome of hepatic veno-occlusive disease (VOD) is one of the most common and serious complications following hematopoietic stem cell transplantation (SCT). High-dose chemotherapy or chemoradiation therapy in the context of autologous and allogeneic SCT can profoundly injure sinusoidal endothelium and hepatocytes within zone 3 of the liver acinus, producing the clinical syndrome of hepatomegaly and/or right upper quadrant pain with jaundice and fluid retention, typically manifest as weight gain. The incidence is variable and ranges from 10 to 60%. Mild to moderate disease is characterized by eventual complete resolution. In contrast, severe disease frequently results in multiorgan failure and death. The purpose of this review is to discuss the pathophysiology and clinical features of VOD, and the current status and future directions of research for both prevention and treatment.

Keywords:
Chemotherapy, high-dose, Endothelial injury, Stem cell transplantation, hematopoietic, Veno-occlusive disease, hepatic, Veno-occlusive disease, prevention and treatment
1.
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984;4:116–122.
2.
Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005–3020.
3.
Richardson PG, Guinan EC: The pathology, diagnosis and treatment of hepatic veno-occlusive disease: Current status and novel approaches. Br J Haematol 1999;107:485–493.
4.
Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB: Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents: Incidence, outcome and risk factors. Hepatology 1997;26:149A.
5.
Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599–3604.
6.
McDonald GB: Venocclusive disease of the liver following marrow transplantation. Marrow Transplant Rev 1993;3:49–56.
7.
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255–267.
8.
Shirai M, Nagashima K, Iwasaki S, Mori W: A light and scanning electron microscopic study of hepatic veno-occlusive disease. Acta Pathol Jpn 1987;37:1961–1971.
9.
Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED: An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980;79:1178–1191.
10.
Shulman HM, Fisher LB, Schoch HG, Kenne KW, McDonald GB: Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994;19:1171–1180.
11.
Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987;127:549–558.
12.
Allen JR, Carstens LA, Katagiri GJ: Hepatic veins of monkeys with veno-occlusive disease. Sequential ultrastructural changes. Arch Pathol 1969;87:279–289.
13.
Ridker PN, McDermont WV: Hepatotoxicity due to comfrey herb tea (letter). Am J Med 1989;87:701.
14.
Traber PG, Chianale J, Gumucio JJ: Physiologic significance and regulation of hepatocellular heterogeneity. Gastroenterology 1988;95:1130–1143.
15.
el Mouelhi M, Kauffman FC: Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 1986;6:450–456.
16.
Deleve LD: Dacarbazine toxicity in murine liver cells: A model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994;268:1261–1270.
17.
Teicher BA, Crawford JM, Holden SA, Lin Y, Cathcart KN, Luchette CA, Flatow J: Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 1988;62:1275–1281.
18.
Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25/1:55–61.
19.
Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lonnerholm G, Smedmyr B, Taube A, Wallin I: Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991;28:130–134.
20.
Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, Bekassy A, Bielenstein M, Abdel-Rehim M, Georen S, Astner L: The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000;25:915–924.
21.
Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484–1494.
22.
Grochow LB: Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20:18–25.
23.
Schuler U, Schroer S, Kuhnle A, Blanz K, Mewes I, Kumbier B, Proksch K, Zeller P, Ehninger G: Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted? Bone Marrow Transplant 1994;14:759–765.
24.
Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB: Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood 1992;80:2425–2428.
25.
DeLeve LD: Glutathione defense in non-parenchymal cells. Semin Liver Dis 1998;18:403–413.
26.
DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996;24:830–837.
27.
Wang X, Kanel GC, DeLeve LD: Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000;31:428–434.
28.
Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, Bandini G, Cirio TM, Tura S: Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996;17:277–280.
29.
Salat C, Holler E, Reinhardt B, Kolb HJ, Seeber B, Ledderose G, Mittermueller J, Duell T, Wilmanns W, Hiller E: Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994;14:747–750.
30.
Salat C, Holler E, Hans-Jochem K, Brigitte R, Pihusch R, Wolfgang W, Hiller E: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997;89:2184–2188.
31.
Richardson P, Krishnan A, Wheeler C, Hoppensteadt D, Tuchin J, Fyfe H, Bierer B, Guinan E, Antin J, Frei E 3rd, Fareed J, Elias A: Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood 1996;88:458a.
32.
Richardson P, Hoppensteadt D, Elias A, Frei E 3rd, Iacobelli M, Guinan E, Fareed J: Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) levels in stem cell transplant (SCT) – Associated veno-occlusive disease (VOD) and changes seen with the use of defibrotide (DF). Blood 1997;90:219a.
33.
Richardson PG, Hoppensteadt DA, Elias AD, Kinchla N, Warren D, Iacobelli M, Guinan EC, Fareed J: Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thromb Haemost 1999;82(suppl):628.
34.
Nurnberger W, Michelmann I, Burdach S, Gobel U: Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998;76:61–65.
35.
Sato Y, Asada Y, Hara S, Marutsuka K, Tamura K, Hayashi T, Sumiyoshi A: Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology 1999;34:66–70.
36.
Bianchi M, Tracey KJ: The role of TNF in complications of marrow transplantation. Marrow Transplant Rev 1993/1994;3:57–61.
37.
Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D’Agay MF, Gluckman E: Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991;63:509–519.
38.
Ferra C, de Sanjose S, Gallardo D, Berlanga JJ, Rueda F, Marin D, de la Banda E, Ancin I, Peris J, Garcia J, Granena A: IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica 1998;83:1082–1087.
39.
Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M, Van Camp B: Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998;22:79–85.
40.
Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL: Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592–1598.
41.
Eltumi M, Trivedi P, Hobbs J, et al: Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993;342:518–521.
42.
Park J-D, Yasui M, Yoshimoto T, Chayama K, Shimono T, Okamura T, Inoue M, Yumura-Yagi K, Kawa-Ha K: Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997;19:915–920.
43.
Rio B, Bauduer F, Arrago JP, Zittoun R: N-terminal peptide of type III procollagen: A marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993;11:471–472.
44.
Eltumi M, Trivedi P, Hobbs JR, Portmann B, Cheeseman P, Downie C, Risteli J, Risteli L, Mowat AP: Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993;342:518–521.
45.
Heikinheimo M, Halila R, Fasth A: Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994;83:3036–3040.
46.
Collins PW, Gutteridge CN, O’Driscoll A, Blair S, Jones L, Aitchison R, Kelsey SM, Chopra R, Goldstone A, Newland AC: Von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992;10:499–506.
47.
Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE: Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990;5:39–42.
48.
Haire WD, Ruby EI, Gordon BG, Patil KD, Stephens LC, Kotulak GD, Reed EC, Vose JM, Bierman PJ, Kessinger A, Armitage JO: Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 1995;274:1289–1295.
49.
Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM: Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993;81:3458–3462.
50.
Sudhoff T, Heins M, Sohngen D, Lenz V, Wehmeier A, Aul C, Meckenstock G, Schneider W, Reinauer H, Heyll A: Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol 1998;60:106–111.
51.
Oh H, Tahara T, Bouvier M, Farrand A, McDonald GB: Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver. Bone Marrow Transplant 1998;22:675–679.
52.
Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB: Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729–1736.
53.
Brown BP, Abu-Yousef M, Farner R, LaBrecque D, Gingrich R: Doppler sonography: A noninvasive method for evaluation of hepatic venocclusive disease. Am J Roentgenol 1990;154:721–724.
54.
Hosoki T, Kuroda C, Tokunaga K, Marukawa T, Masuike M, Kozuka T: Hepatic venous outflow obstruction: Evaluation with pulsed duplex sonography. Radiology 1989;170:733–737.
55.
Nicolau C, Concepcio B, Carreras E, Bosch J, Bianchi L, Gilabert R, Vilana R: Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver. J Ultrasound Med 1993;12:437–440.
56.
Sonneveld P, Lameris JS, Cornelissen J, Ogilvie A, Lowenberg B: Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment. Bone Marrow Transplant 1998;21:731–734.
57.
van den Bosch MA, van Hoe L: MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation. Eur Radiol 2000;10:1290–1293.
58.
Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Tassies MD, Garcia-Pagan JC, Marti JM, Bosch J: Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993;11:21–26.
59.
Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, McDonald GB: Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995;59:1015–1022.
60.
Rubenfeld GD, Crawford SW: Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med 1996;125:625–633.
61.
Fink J, Cooper M, Burkhart K, McDonald GB, Zager RA: Marked enzymuria following bone marrow transplantation: A correlate of veno-occlusive disease-induced ‘hepato-renal syndrome’. J Am Soc Nephrol 1995;6:1655–1660.
62.
Zager RA, O’Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 1989;13:210–216.
63.
Tse WT, Beyer W, Pendleton JD, Richardson P, Guinan EC: Genetic polymorphisms in glutathione S-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD). American Society of Hematology. J Am Soc Hematol 2000;96:390a.
64.
Haire WD, Cavet J, Pavletic SZ, Tarantolo SR, Norden J, Middleton PG: Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation (ABSCT). American Society of Hematology. J Am Soc Hematol 2000;96:584a.
65.
Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM: Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:975–981.
66.
Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, Okamoto S, Aotsuka N, Saito K, Nishimura M, Oh H, Matsuzaki M, Takahashi S, Yonekura S: The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000;64:32–38.
67.
Ruutu T, Eriksson B, Remes K, Vilin L, Remberger M, Parkkali T, Juvoner E, Ringden O: Ursodiol prevention of hepatic complications in allogeneic stem cell transplantation: Results of a prospective, randomized, placebo-controlled trial (abstract). Bone Marrow Transplant 1999;23:756.
68.
Goringe AP, Brown S, O’Callaghan U, Rees J, Jebb S, Elia M, Poynton CH: Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998;21:829–832.
69.
Jonas CR, Puckett AB, Jones DP, Griffith DP, Szeszycki EE, Bergman GF, Furr CE, Tyre C, Carlson JL, Galloway JR, Blumberg JB, Ziegler TR: Plasma antioxidant status after high-dose chemotherapy: A randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 2000;72:181–189.
70.
Ringden O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J: N-Acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000;25:993–996.
71.
Ferra C, Sanjose S, Lastra CF, Marti F, Marino EL, Sureda A, Brunet S, Gallardo D, Berlanga JJ, Garcia J, Granena A: Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 1997;20:1075–1080.
72.
Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger WI, Bowden RA, McDonald GB, Schubert M, et al: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993;82:2025–2030.
73.
Khoury H, Adkins D, Trinkaus K, Brown R, Westervelt P, Vij R, Goodnough LT, Di Persio JF: Treatment of hepatic veno-occlusive disease with high dose corticosteroids: An update on 28 stem cell transplant recipients (abstract). Blood 1998;92(suppl 1):1132.
74.
Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS: Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996;18:185–191.
75.
Budinger MD, Bouvier M, Shah A, McDonald GB: Results of a phase 1 trial of anti-thrombin III as prophylaxis in bone marrow transplant patients at risk for venocclusive disease (abstract). Blood 1996;88:172a.
76.
Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, Cass Y, Gillis S, Chetrit A, Slavin S, Eldor A: Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996;61:1067–1071.
77.
Bearman SI, Shuhart MC, Hinds MS, McDonald GB: Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992;80:2458–2462.
78.
Leahey AM, Bunin NJ: Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996;17:1101–1104.
79.
Bearman SI, Lee JL, Baron AE, McDonald GB: Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501–1506.
80.
Haire WD, Stephens LC, Ruby EI: Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT) – Results of a pilot study (abstract). Blood 1996;88:458a.
81.
Strasser SI, McDonald GB: Gastrointestinal and hepatic complications; in Forman SJ, Blume KG, Thomas ED (eds): Hematopoietic Cell Transplantation, ed 2. Oxford, Blackwell Scientific, 1998.
82.
Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT, Morris CL: Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997;20:871–878.
83.
Ibrahim A, Pico JL, Maraninchi D, Zambon E, Attal M, Brault P, Tilly H, Blaise D, Hayat M: Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant 1991;7 (suppl): 53.
84.
Baglin TP, Harper P, Marcus RE: Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990;5:439–441.
85.
Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC: Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation (letter). Lancet 1992;339:1057.
86.
Rosti G, Bandini G, Belardinelli A, Calori E, Tura S, Gherlinzoni F, Miggiano C: Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation (letter). Lancet 1992;339:1481–1482.
87.
Ringden O, Wennberg L, Ericzon BG, Kallman R, Astrom M, Duraj F, Soderdahl G, Tyden G, Groth CG: Alteplase for hepatic veno-occlusive disease after bone marrow transplantation (letter). Lancet 1992;340:546–547.
88.
Feldman L, Gabai E, Milovic V, Jaimovich G: Recombinant tissue plaminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient. Bone Marrow Transplant 1995;16:727–731.
89.
Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF: Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile. Bone Marrow Transplant 1996;18:633–636.
90.
Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma E, Ido M, Ito M, Sakurai M: Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1. Leuk Res 1995;19:477–480.
91.
Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, Winiarski J, Tyden G: Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996;62:1076–1080.
92.
Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW, Suh C, Lee JS, Kim WK, Lee YS, Kim SH: Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): Efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996;11:118–126.
93.
Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP: Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994;46:194–198.
94.
Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G: Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999;24:1311–1314.
95.
Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, Saso R, Tait D, Treleaven JG, Powles RL: Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999;23:803–807.
96.
Schlitt HJ, Tischler HJ, Ringe B, Raddatz G, Maschek H, Dietrich H, Kuse E, Pichlmayr R, Link H: Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation – Clinical and immunological considerations. Bone Marrow Transplant 1995;16:473–478.
97.
Fried MW, Connaghan DG, Sharma S, et al: Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996;24:588–591.
98.
Smith FO, Johnson MS, Scherer LR, et al: Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996;18:643–646.
99.
Alvarez R, Banares R, Casariego J, Echenagusia A, Simo G, Alvarez E, Serrano D, Diez-Martin JL: Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol 2000;23:177–180.
100.
Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D, Cedro A, Salvetti L, Mantovani M, Prino G: Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238:327–334.
101.
Bracht F, Schror K: Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994;200:933–936.
102.
Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V: Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 1990;40:337–350.
103.
Coccheri S, Biagi G: Defibrotide. Cardiovasc Drug Rev 1991;9:172–196.
104.
Fareed J: Modulation of endothelium by heparin and related polyelectrolytes; in Nicolaides A, Novo S (eds): Advances in Vascular Pathology 1997. Amsterdam, Elsevier Science, 1997.
105.
Zhou Q, Chu X, Ruan C: Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994;71:507–510.
106.
Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F: Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988;35:151–156.
107.
Ulutin ON: Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost 1993;19:186–191.
108.
Jamieson A, Alcock P, Tuffin DP: The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996;10:27–35.
109.
Bonomini V, Vangelista A, Frasca GM: A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Nephron 1984;37:144.
110.
Viola F, Marubini S, Coccheri G, Nenci G: Improvement of walking distance by defibrotide in patients with intermittent claudication: Results of a randomized, placebo-controlled study (the DICLIS study). Thromb Haemost 2000;83:672–677.
111.
Falanga A, Marchetti M, Vignoli A, Barbui T: Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood 1999;94:146a.
112.
Falanga A, Marchetti M, Vignoli A, Barbui T: Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cells from macro- and micro-vessels. Blood 2000;96:53a.
113.
Palmer KJ, Goa KL: Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259–294.
114.
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC: Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737–744.
115.
Abecasis M, Ferreira I, Guimaraes A, Machado A: Defibrotide as salvage therapy for hepatic veno-occlusive disease (VOD) (abstract). Bone Marrow Transplant 1999;23(suppl 1):749.
116.
Salat C, Pihusch R, Fries S, et al: Successful treatment of veno-occlusive disease with defibrotide – A report of two cases (abstract). Bone Marrow Transplant 1999;23(suppl 1): 757.
117.
Zinke W, Neumeister P, Linkesch W: Defibrotide – An approach in the treatment of severe veno-occlusive disease? (abstract). Bone Marrow Transplant 1999;23(suppl 1): 760.
118.
Jenner MJ, Micallef IN, Rohatiner AZ, Kelsey SM, Newland AC, Cavenagh JD: Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. Med Oncol 2000;17:333–336.
119.
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T: Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000;111:1122–1129.
120.
Richardson PG, Mukarami C, Warren D, Jin Z, Neuberg D, Elias AD, Antin J, Soiffer R, Bearman SI, Vredenburgh J, Vogelsang G, Hoppensteadt D, Fareed J, Iacobelli M, McDonald GB, Guinan EC: Multi-institutional emergency use of defibrotide (DF) in 75 patients post-SCT with severe VOD and multi-system organ failure (MOF): Response without significant toxicity in a high risk population. Blood 2000;96:585a.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.